Audit: QRS - Lemongrass to Treat Cancer

Audit conducted on 10/23/2026 17:27 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	85
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, Protocol, gates, tiers, markers and qualitative items each trace to ER passages (Conclusion, Therapeutic Protocol, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring Protocol)
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges kept: “theoretical” on every interaction, “is speculative”, “one small study without a comparison group”, “No standard anticancer protocol exists”, “No established target”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; contraindications mirror the ER’s “Populations who should avoid Lemongrass”
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER avoid list, interactions from the interaction lists, benefits and risks from their own sections
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names or NCT IDs; FOLFOX appears in the ER for the same interaction

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s cautious, evidence-weighted tone
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Stop/review wording in cadence is the ER’s own
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No second-person address
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms (eGFR, Glutathione S-transferase, Nephrotoxic, CYP labels) are ER labels or marker names carried verbatim
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Framing stresses keeping standard treatment and kidney monitoring for a risk-aware reader with cancer
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“oral essential oil”, “rinsed, not ingested”; no lay route-of-administration phrasing

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, tier labels and column headers unchanged
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template variables present; marker_# expanded to 1-6, qualitative_item_# to 1-5
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff against template shows changes only inside data-qrs-var spans, display:none on empty tiers, and the metadata block

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty tiers (benefits_medium, risks_high, risks_medium) hidden; “Unknown” and “No established target” are ER wording for carried facts
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels reused (e.g., “Tea (most studied form)”, “Mouthwash (gum health)”, interaction labels)
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Only example-list trimming and optional gloss removal (e.g., “(kidney-damaging)”), as permitted
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, untrimmed example lists, optional glosses or repetitions found

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment directly follows doctype (line 2)
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration value quoted because it contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.23 matches QRS.md
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1023-1655
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Opus
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Opus 5.5
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Lemongrass to Treat Cancer - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/23/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Lemongrass, a cooking herb promoted against cancer”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the Conclusion’s evidence verdict, human benefits, safety signals and displacement hazard
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist terms
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid populations listed
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses (e.g., rat data and MSKCC wording after “Pregnant women”) stripped
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(no source gives a threshold)” kept
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, as the ER names avoid populations
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 14 ER interactions listed; none duplicates a contraindication
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanisms, consequences and mitigations stripped
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists trimmed but kept; “during chemotherapy or radiotherapy” window kept
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, as the ER names interactions
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Tea, mouthwash and extracts/oil bullets from Therapeutic Protocol
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Gum inflammation, anxiety, anticancer effect
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Two High benefits first, Speculative anticancer effect last
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects exist
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER subheading labels only
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_medium hidden with display:none

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER subheading labels only
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_medium hidden with display:none

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	All six ER table biomarkers listed
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets as in ER; purposes in a few words
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢	Cadence matches ER Ongoing monitoring paragraph
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All five ER qualitative markers listed
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers

Issues 10/23/2026 17:27

Pass rate 100.00%. No issues found.

Issues 10/23/2026 17:22

1. 2.7 — Unexplained acronym in protocol: Protocol action_1_sub (line 448) reads “eGFR fell by day 30 at every dose”; “eGFR” is unexplained medical jargon outside any ER label where plain “kidney function” conveys the same fact.

Fixes 10/23/2026 17:22

1. 2.7 — Unexplained acronym in protocol: Replaced “eGFR fell by day 30 at every dose” with “kidney function fell by day 30 at every dose” in action_1_sub.

Issues 10/23/2026 17:20

1. 1.1 / 7.4 — Lede overstates speculative scope: At a Glance (QRS line 431) says “any benefit, from cell and animal studies only, is speculative”, but ER line 410 limits this to “any anticancer benefit is speculative” and rates gum and anxiety benefits High.

Fixes 10/23/2026 17:20

1. 1.1 / 7.4 — Lede speculative scope narrowed: Changed “any benefit, from cell and animal studies only, is speculative” to “any anticancer benefit, from cell and animal studies, is speculative”, matching ER line 410 and keeping the lede at 70 words.

Issues 10/23/2026 17:15

1. 2.14 — Lay “kidney filtering” phrasing: The lede (line 431, “daily tea lowered kidney filtering”) and action_1_sub (line 448, “kidney filtering fell by day 30”) use lay wording in the document’s own voice where clinical terminology (“kidney function” / eGFR) is expected.

Fixes 10/23/2026 17:15

1. 2.14 — Lay “kidney filtering” phrasing: Changed the lede’s “daily tea lowered kidney filtering” to “daily tea lowered kidney function” and action_1_sub’s “kidney filtering fell by day 30” to “eGFR fell by day 30”, matching the ER Protocol wording.

Issues 10/23/2026 17:12

1. 1.2 / 1.3 — Lede drops “documented” hedge: The at-a-glance at line 431 says “the largest, indirect hazard is replacing standard treatment”, while the ER Conclusion says “The largest documented hazard is indirect”; dropping “documented” removes the ER’s hedge and turns its claim into an unqualified one.

Fixes 10/23/2026 17:12

1. 1.2 / 1.3 — Restored “documented” hedge: Changed the lede’s “the largest, indirect hazard is replacing standard treatment” to “the largest documented hazard is indirect: replacing standard treatment”, matching the ER Conclusion. To stay within 70 words, “seen only in laboratory dishes and rodents” became “from cell and animal studies only”.

Issues 10/23/2026 17:07

1. 1.1 — Anxiety benefit generalized: The At a Glance at line 431 says “less gum inflammation and anxiety”, while the ER Conclusion limits the anxiety benefit to lemongrass “from its scent” and reports tea had no anxiety effect.
2. 1.2 — Indirect hedge dropped: The At a Glance at line 431 omits the ER Conclusion’s qualifier that the largest documented hazard is “indirect”.
3. 1.3 — Hazard scope broadened: “replacing standard treatment is the largest documented hazard” at line 431 drops the ER’s “for curable cancers” scope, strengthening the ER claim.

Fixes 10/23/2026 17:07

1. 1.1 — Anxiety benefit tied to scent: Changed “less gum inflammation and anxiety” to “less gum inflammation and less anxiety from its scent” in the At a Glance, matching the ER Conclusion.
2. 1.2 / 1.3 — Indirect hazard and scope: Replaced “replacing standard treatment is the largest documented hazard” with “the largest, indirect hazard is replacing standard treatment for curable cancer”, restoring the ER’s “indirect” and “curable cancers” qualifiers; the opening sentence was tightened to keep the lede at 70 words.

Issues 10/23/2026 17:02

1. 4.5 — Optional glosses and examples: The Key Interactions labels at lines 551–562 carry optional glosses (“(kidney-damaging)”, “drugs that increase urine output:”, “non-steroidal anti-inflammatory drugs:”) and untrimmed example lists of three or four drugs (e.g., “cyclophosphamide, bupropion, theophylline, clozapine”).
2. 7.5 — Specialist term in lede: The At-A-Glance at line 431 says “one small uncontrolled study”; “uncontrolled” is a research term a non-specialist would not read as “without a comparison group”.

Fixes 10/23/2026 17:02

1. 4.5 — Glosses and example lists trimmed: Removed the optional glosses from the Nephrotoxic, Diuretics and NSAIDs labels and trimmed every three- or four-drug example list in Key Interactions to two ER examples (e.g., “cyclophosphamide, bupropion, theophylline, clozapine” → “cyclophosphamide, theophylline”).
2. 7.5 — Plain-language study description: Replaced “one small uncontrolled study” with “one small study without a comparison group” and dropped “and tea” from the opening so the lede stays at 70 words.

Issues 10/23/2026 16:59

1. 1.3 — Lede drops “documented” qualifier: The At-A-Glance at line 431 says “replacing standard treatment is the largest hazard”, while the ER Conclusion says “The largest documented hazard is indirect”.
2. 2.14 — Lay route phrasing: Protocol action_2_sub at line 459 reads “rinsed, not swallowed” instead of formal terminology (“rinsed, not ingested”).
3. 4.5 — Repetition and optional gloss: time_1_sub at line 487 restates the action_2 regimen (“Twice-daily 0.25% oil mouthwash”), time_2_sub at line 498 repeats “single-session” from its value, and action_1_sub at line 448 carries the optional gloss “(eGFR)”.

Fixes 10/23/2026 16:59

1. 1.3 — Restored “documented” qualifier: Changed the lede ending from “the largest hazard” to “the largest documented hazard”, matching the ER Conclusion; dropped “any” from “so any benefit is speculative” to stay within 70 words.
2. 2.14 — Formal route phrasing: Changed action_2_sub from “rinsed, not swallowed” to “rinsed, not ingested”.
3. 4.5 — Removed repetition and gloss: Replaced time_1_sub with “Small, short randomized trials”, removed “single-session” from time_2_sub, and removed the optional gloss “(eGFR)” from action_1_sub.